Overview

Overview
 
LeadArtis´s current business model includes the definition of an in-house pipeline and partnerships with other companies oriented to the combination of our technology with that of our collaborators.
 
Trimerbody® can be adapted to numerous protein configurations. There are multiple options to establish such relationships. Should you believe that our technology is of interest, we would be pleased to tell you more details and accommodate flexible avenues for collaboration schemes.  
 
 

Latest News

Leadartis announces the publication "An Fc-free EGFR-specific 4-1BB-agonistic trimerbody displays broad anti-tumor activity in humanized murine cancer models without toxicity” in Clinical Cancer Research
02-04-2021
Leadartis reaches a major milestone with the demonstration of absence of toxicity of its drug candidate in preclinical models
13-01-2021

Leadartis reaches a major milestone with the demonstration of...

Leadartis featured in EXPANSION as a ‘Start up’ that leads the fight against cancer
10-11-2020

...